

The Effect of Obesity on Pain Severity and Pain Interference

Jade Basem, B.A.[†], Robert S. White, M.D.[†], Stephanie A. Chen, M.D.[‡], Elizabeth Mauer, M.S.[§],

Michele L. Steinkamp, R.N.[†], Charles E. Inturrisi, Ph.D.[⊥], Lisa Witkin, M.D.[†]

From the

[†]Department of Anesthesiology, Weill Cornell Medicine, New York, NY

[‡]Department of Anesthesiology, Columbia University Medical Center, New York, NY

[§]Department of Healthcare Policy & Research, Weill Cornell Medicine, New York, NY

[⊥]Department of Pharmacology, Weill Cornell Medicine, New York, NY

Address correspondence to:

Lisa Witkin, MD, Department of Anesthesiology, Center for Comprehensive Spine Care at Weill Cornell Medicine, 240 East 59th Street, New York, NY 10022 (email: lrw9003@med.cornell.edu)

Conflicts of Interest:

Charles Inturrisi receives compensation as described in a 2017 license agreement between Charles E. Inturrisi (and Paolo Manfredi) and Relmada Therapeutics, Inc. for the development of compounds (including d-methadone) for the treatment of depression. Otherwise, the authors declare no conflicts of interest.

Funding:

The authors have no sources of funding to declare for this manuscript.

Ethical Approval Statement:

This study was approved by the Institutional Review Board and Clinical Study Evaluation Committee of Weill Cornell Medicine. A full HIPAA waiver and full waiver of informed consent was requested as this study involved no more than minimal risk and was a retrospective chart review. The full HIPAA waiver and full waiver of informed consent was granted for all subjects.

Running Head: Obesity, Pain Severity, and Pain Interference

1 **ABSTRACT**

2 **Background and objectives** Obesity is one of the most prevalent comorbidities associated with
3 chronic pain, the experience of which can severely interfere with activities of daily living and
4 increase the utilization of clinical resources. Obesity is also a risk factor for increased pain
5 severity (pain intensity) and pain interference (pain related disability). We hypothesize that a
6 higher level of obesity, as measured by body mass index (BMI), would be associated with
7 increased levels of pain severity and interference in a population of chronic pain clinic patients.

8 **Methods** Participant data was pulled from a multi-site chronic pain outpatient database from
9 7/8/2011 to 10/17/2016. The Brief Pain Inventory (BPI), opioid prescriptions, and basic
10 demographic information were queried and we categorized participants into three different
11 ordinal categories based on recorded BMI levels (underweight, normal and overweight, obese).
12 Bivariate analyses were performed to compare pain outcomes by BMI and by other
13 demographic/clinical patient characteristics. Multivariable linear regressions were constructed to
14 model each of four pain severity scores in addition to total pain interference score. All models
15 examined BMI as the primary predictor, controlling for age, receipt of a pain procedure within
16 45 days prior to the pain clinic encounter, opioid prescription within 45 days prior to the
17 encounter, and diagnosis. The total pain interference model additionally included pain severity
18 (as measured by worst pain in the past 24 hours) as a covariate.

19 **Results** 2509 patients were included in the study. The median BMI was 27 and the median age
20 was 59 years. 77% of patients were diagnosed with musculoskeletal pain conditions. Bivariate
21 tests revealed significant differences between BMI groups for all pain severity scores and for
22 total pain interference score. On multivariable modelling controlling for age, pain procedure
23 within 45 days prior to pain clinic encounter, opioid prescription with 45 days prior, and
24 diagnosis, obese patients had significantly higher pain severity (as measured by worst, least,
25 average, and current pain in the past 24 hours) as well as higher pain interference (as measured
26 by the overall pain interference score) than normal weight and overweight patients.

27 **Conclusion** In our study of pain clinic patients, obesity was found to be associated with
28 increased pain severity and pain interference. We believe that this relationship is multifactorial
29 and bidirectional. Pain physicians should consider the impact of obesity when addressing pain
30 management for patients.

31 **INTRODUCTION**

32 The Institute of Medicine estimates that 100 million United States adults are affected by chronic
33 pain, which costs the nation \$635 billion yearly in medical treatment and lost productivity ¹. Pain
34 is a common experience for the general population, as 11.2% of adults report daily pain
35 symptoms ². Pain is the most common reason patients seek medical attention with approximately
36 one-fifth of ambulatory medical care associated with pain as a primary symptom or diagnosis ^{3;4}.
37 The experience of pain is complex, as chronic pain is a multidimensional hierarchical construct
38 that consists of both the sensation of pain severity and interference in engagement with
39 activities⁵. In addition, a threshold effect occurs where low levels of pain intensity are not
40 associated with functional interference; however, higher levels of pain intensity increase the
41 probability of interference in a nonlinear fashion ⁵⁻⁷.

42
43 One of the prevalent comorbidities that is commonly associated with chronic pain is obesity ⁸.
44 Data from the National Health and Nutrition Examination Survey from 2015-2016 demonstrates
45 that 39.8% of United States adults were obese ⁹. The presence of obesity is associated with an
46 increase in self-reported bodily pain measures and pain related disability, a decrease in
47 psychological well-being, and reduced physical functioning ¹⁰⁻¹². The relationship between pain
48 and obesity is likely multi-directional and multi-factorial, including central pain and
49 inflammatory pathways ¹³⁻¹⁵. Provider prescriptions of non-steroidal anti-inflammatory agents
50 used to treat pain are higher amongst obese patients ^{16;17}.

51
52 Given the prevalence of obesity in the general and chronic pain populations and its effect on
53 clinical outcomes, it is important to understand how obesity affects the validated pain outcomes

54 commonly used in clinical practice, including pain severity and pain interference. Previous
55 research has elucidated higher pain scores in female, osteoarthritic, and postoperative patients
56 with obesity. However, these studies are often limited by small or homogeneous cohorts, or
57 examine outcomes that are not commonly used by chronic pain providers in a clinical setting ¹⁸⁻
58 ²². No major study to date has analyzed the impact that obesity has on pain severity and
59 interference scores in a general chronic pain population. Herein, we seek to further explore the
60 association of obesity as a risk factor for pain related outcomes. Outcomes of interest include:
61 pain severity and pain interference. We hypothesized that a higher level of obesity, as measured
62 by body mass index (BMI), would be associated with increased pain severity and pain
63 interference.
64

65 **METHODS**

66 **Patient Population**

67 We collected data from a longitudinal observational cohort of chronic pain outpatients seen in
68 the Weill Cornell Medicine (WCM) pain medicine clinic from 7/8/2011 to 10/17/2016. These
69 patients are part of a larger tri-institutional chronic pain database herein referred to as The
70 Registry, which encompasses Pain Services data from WCM, Hospital for Special Surgery and
71 Memorial Sloan-Kettering Cancer Center (MSKCC), New York, New York. The Registry
72 design, enrollment procedures, data collection and analysis have been previously described ²³. A
73 data sharing agreement exists between WCM and the Health System Innovation and Research
74 Program, University of Utah School of Medicine, Salt Lake City, UT, who maintain the database
75 and assist with the data analysis. Health System Innovation and Research Program merges the
76 coded PRO data in Webcore with data captured in EPIC to form a complete coded limited data
77 set for The Registry ²³. While patient identifiers are removed, the coded data contains encounter
78 dates, and therefore the data represents a limited data set according to the HIPAA Privacy Rules.
79 Patient data is collected under standard of care and is part of a quality improvement program.

80

81 The inclusion criteria for this study included all chronic pain patients, as defined by at least one
82 clinic attendance. If multiple visit had data recorded, the first entry was the value used in
83 analysis. The original exclusion criteria for The Registry was absence of a chronic pain
84 diagnosis, but for this study the exclusion criteria also included patients without BMI data and
85 without a specific type of chronic pain diagnosis for the encounter ²³.

86

87 Patient specific factors and process factors were obtained for each patient at each encounter.
88 These factors included: demographics (Age, Sex, Marital Status, Ethnicity, Language, Religion,
89 and Payor), vitals (height, weight, BP, Temperature, pulse rate), diagnoses, CPT codes,
90 medications, and the survey data which included the pain severity and pain interference scores.
91 BMI was calculated as weight in kilograms divided by the square of height in meters.
92 Participants were categorized into three groups based on BMI: underweight (BMI <18.5),
93 normal weight and overweight (BMI = 18.5-29.9), and obese (BMI ≥30); the normal weight
94 and overweight category was used as the reference in all models.

95
96 During each outpatient pain clinic encounter, pain information was collected using the Brief Pain
97 Inventory (BPI) short form. The BPI short form is a validated tool that assesses the presence of
98 pain; pain severity, pain interference, percentage of relief provided by pain treatments or
99 medications (0-100%), and the location of pain at 22 pre-specified sites assessed over a 24-hour
100 recall period²⁴. Patients describe their pain severity on a scale from 0 (“No Pain”) to 10 (“Pain
101 as bad as you can imagine”) when their pain is at its worst, least, on average, and if they are
102 experiencing pain right now⁷. Pain interference is measured on seven daily functions, including
103 general activity, mood, walking ability, normal work (includes both work outside the house and
104 housework), relations with other people, sleep, and enjoyment of life. Each pain interference
105 measure is assessed through a rating scale from 0 (“Does not Interfere”) to 10 (“Completely
106 Interferes”).

107

108 **Estimating Opioid Use, Dosage, and Duration**

109 Opioid medications that were being taken and prescribed at each encounter were abstracted from
110 EPIC. For patients included in the Registry, we captured all the opioids recorded for each
111 encounter backward to 11/1/2010 (this date was specified as when clinicians were required to
112 perform medication reconciliation in EPIC and therefore represents the most reliable data).
113 Resultantly, opioid duration was measured from 11/1/2010 to 9/1/2016, including opioid use
114 prior to entry into the Registry. Based on a discussion with the pain clinicians on patient opioid
115 prescription filling practices, we looked back at least 45 days from their clinic visit for a
116 schedule 2 opioid prescription or refill. We excluded patients receiving intrathecal opioids from
117 this analysis.

118

119 **Statistical analysis**

120 Statistical analyses were performed using R Version 3.5.3 (Vienna, Austria)²⁵. Bivariate analyses
121 were performed to compare pain outcomes by demographic/clinical patient characteristics as
122 well as to compare demographic/clinical patient characteristics by bmi groups (underweight,
123 normal and overweight, and obese). Bivariate tests included independent two-sample t-tests,
124 Analysis of Variance (ANOVA), or Chi-Squared/Fisher's Exact tests, as appropriate.
125 Nonparametric equivalents were used for violations of normality.

126

127 To examine the effect of BMI on pain severity and pain interference we fit multivariable linear
128 regression models to our data; regression coefficients along with their 95% confidence intervals
129 were reported. We developed separate models for each of the four pain severity scores (worst,
130 least, average, and current) and for total pain interference with the additional inclusion of pain
131 severity as a covariate. All models adjusted for demographic and clinical variables available and

132 considered relevant (age, pain procedure within 45 days prior, opioids prescribed within 45 days
133 prior, and diagnosis). All statistical tests were 2-sided with statistical significance assigned at an
134 alpha level of 0.05.

135

136 **RESULTS**

137 A total of 2,509 patients were included in the study. The cohort's median age was 59 years,
138 median BMI was 27 kg/m², and the most common pain diagnosis category was musculoskeletal
139 pain (77%). About 20% of the patients received a pain procedure within 45 days prior to the pain
140 clinic encounter, and half of the patients (53%) received an opioid prescription within 45 days
141 prior. Differences between BMI groups are shown in Table 1. Some statistical significance
142 represents underlying differences in the spread of pain scores, as shown through the range.
143 Bivariate tests revealed significant differences between BMI groups for all pain severity scores
144 and for total pain interference score (Table 2).

145

146 For each multivariable model looking at pain severity (as either the worst, least, average, or
147 current pain within the past 24 hours), obese patients demonstrated significantly higher scores
148 than normal weight patients after controlling for age, pain procedure within the 45 days prior to
149 the pain clinic encounter, opioid prescription within the 45 days prior, and diagnosis category.
150 Specifically, obese patients had an average 0.354 higher severity score at their worst pain within
151 the past 24 hours, 0.556 at their least pain within the past 24 hours, 0.382 at their average pain in
152 the past 24 hours, and 0.625 at their current pain than normal weight patients. Similarly, for the
153 multivariable model looking at overall pain interference, obese patients demonstrated
154 significantly higher scores than normal weight patients after controlling for the same factors in
155 addition to pain severity (as measured as the worst pain in the past 24 hours). Specifically, obese
156 patients had an average 0.276 higher overall pain interference score than normal weight patients.

157

158 Confirming our assumption, pain severity (as measured as the worst pain in the past 24 hours)
 159 was significantly associated with overall pain interference; specifically, overall pain interference
 160 increased on average by 0.689 points for each additional point higher in worst pain severity. An
 161 additional result of note is that underweight patients also showed a significant difference
 162 compared to normal weight in the pain now severity model ($p=0.033$).

163
 164 Opioid use was statistically significant for each pain severity and pain interference outcome used
 165 in multivariable modeling ($p<0.0001$ for all outcomes). 58.3% of obese patients and 63.2% of
 166 underweight patients were prescribed opioid medications within 45 days prior compared to only
 167 50.7% of normal weight patients ($p=0.001$), with all BMI groups being more likely to take pain
 168 medications than not. Differences between BMI groups also existed when looking specifically at
 169 IR opioid medications and ER opioid medications prescribed. 56.3% of obese patients and 61.8%
 170 of underweight patients were prescribed IR opioid medications compared to 47.4% of
 171 normal/overweight patients ($p <0.001$). About 14% of both obese and normal/overweight
 172 patients were prescribed ER opioid medications compared to 25% of underweight patients
 173 ($p=0.041$).

174

175 **Table 1: Differences Between BMI Groups**

	BMI <18.5	BMI 18.5-29.99	BMI ≥30	p value	N
Weight	106 [98.8;118]	154 [135;175]	215 [190;243]	<0.001	2509
Height	65.3 [63.7;69.0]	66.0 [63.0;69.0]	65.5 [63.9;69.0]	0.163	2509
Age (continuous)	52.2 [36.8;69.5]	59.9 [46.4;71.7]	59.9 [49.4;68.6]	0.093	2509
Age (categorical)				<0.001	2509
18-44	25 (36.8%)	401 (23.5%)	120 (16.3%)		
45-64	23 (33.8%)	645 (37.8%)	364 (49.6%)		
65+	20 (29.4%)	661 (38.7%)	250 (34.1%)		

Pain procedure with 45 days prior				0.743	2509
No	57 (83.8%)	1366 (80.0%)	588 (80.1%)		
Yes	11 (16.2%)	341 (20.0%)	146 (19.9%)		
Pain procedure with 45 days after				0.69	2509
No	56 (82.4%)	1332 (78.0%)	576 (78.5%)		
Yes	12 (17.6%)	375 (22.0%)	158 (21.5%)		
Opioid medication within 45 days prior				0.001	2509
No	25 (36.8%)	841 (49.3%)	306 (41.7%)		
Yes	43 (63.2%)	866 (50.7%)	428 (58.3%)		
IR opioid medications within 45 days prior				<0.001	2509
No	26 (38.2%)	898 (52.6%)	321 (43.7%)		
Yes	42 (61.8%)	809 (47.4%)	413 (56.3%)		
ER opioid medications within 45 days prior				0.041	2509
No	51 (75.0%)	1468 (86.0%)	627 (85.4%)		
Yes	17 (25.0%)	239 (14.0%)	107 (14.6%)		
Pain Severity and Interference					
Worst pain, 24 hours	8.00 [6.00;9.00]	8.00 [6.00;9.00]	8.00 [6.00;9.00]	<0.001	2425
Least pain, 24 hours	5.00 [3.00;7.00]	4.00 [2.00;6.00]	5.00 [2.00;7.00]	<0.001	2415
Average pain, 24 hours	6.00 [4.25;8.00]	6.00 [4.00;7.75]	6.00 [5.00;8.00]	<0.001	2371
Pain now- current	6.50 [4.00;8.00]	5.00 [3.00;8.00]	6.00 [4.00;8.00]	<0.001	2370
General Activity	7.00 [5.00;9.00]	6.00 [4.00;8.00]	7.00 [5.00;9.00]	<0.001	2345
Mood	7.00 [4.00;9.00]	6.00 [3.00;8.00]	6.00 [3.00;8.00]	0.001	2330
Walking	6.00 [3.00;9.00]	5.00 [2.00;8.00]	7.00 [4.00;9.00]	<0.001	2339
Normal work	7.00 [5.00;9.00]	6.00 [4.00;9.00]	7.00 [5.00;9.00]	<0.001	2315
Relations with others	5.00 [1.25;7.00]	4.00 [0.00;7.00]	5.00 [0.00;7.00]	0.014	2294
Sleep	6.50 [3.00;8.00]	5.00 [2.00;8.00]	6.00 [3.00;9.00]	0.002	2318
Enjoyment of life	8.00 [5.00;9.00]	7.00 [4.00;8.00]	7.00 [5.00;9.00]	<0.001	2297
Interference Total Score	6.29 [5.00;7.71]	5.57 [3.29;7.43]	6.46 [4.14;8.00]	<0.001	2359
Diagnosis Category				0.001	2509
Musculoskeletal	44 (64.7%)	1298 (76.0%)	578 (78.7%)		
Neuropathic	8 (11.8%)	207 (12.1%)	90 (12.3%)		
Other	11 (16.2%)	135 (7.91%)	29 (3.95%)		
Unclear/unknown	5 (7.35%)	67 (3.93%)	37 (5.04%)		

176

177

178 **Table 2: Multivariable Model Results**

		Pain Severity (Worst 24 Hours)		Pain Severity (Least 24 Hours)	
		Estimate (95% CI)	P-Value	Estimate (95% CI)	P-Value
BMI	Underweight	0.284 (-0.315, 0.884)	0.353	0.667 (-0.049, 1.383)	0.068

	ref=Normal				
	Weight/Overweight				
	Obese	0.354 (0.139, 0.569)	0.001	0.556 (0.301, 0.811)	0.000
Age		0.000 (-0.006, 0.006)	0.936	-0.002 (-0.009, 0.005)	0.545
Pain procedure within 45 days prior		0.011 (-0.232, 0.253)	0.93	-0.157 (-0.445, 0.132)	0.287
Opioid prescription within 45 days prior		0.715 (0.517, 0.914)	<0.001	0.655 (0.419, 0.890)	0.000
Diagnosis	ref=Muskuloskeletal				
	Neuropathic	-0.004 (-0.304, 0.296)	0.978	-0.127 (-0.483, 0.230)	0.486
	Other	0.061 (-0.326, 0.448)	0.758	-0.491 (-0.949, -0.32)	0.36
	Unclear/unknown	-0.290 (-0.764, 0.185)	0.232	-0.338 (-0.901, 0.224)	0.239
	Worst Pain				
		Pain Severity (Average 24 Hours)		Pain Severity (Current)	
		Estimate (95% CI)	P-Value	Estimate (95% CI)	P-Value
BMI	Underweight	0.437 (-0.146, 1.020)	0.142	0.748 (0.061, 1.434)	0.033
	ref=Normal				
	Weight/Overweight				
	Obese	0.382 (0.171, 0.592)	0.000	0.625 (0.376, 0.874)	0.25
Age		0.003 (-0.003, 0.008)	0.391	-0.008 (-0.015, -0.001)	0.25
Pain procedure within 45 days prior		-0.118 (-0.358, 0.121)	0.332	-0.079 (-0.360, 0.202)	0.580
Opioid prescription within 45 days prior		0.595 (0.400, 0.790)	0.000	0.748 (0.519, 0.978)	0.000
Diagnosis	ref=Muskuloskeletal				
	Neuropathic	-0.048 (-0.341, 0.245)	0.748	-0.104 (-0.450, 0.243)	0.558
	Other	-0.149 (-0.530, 0.232)	0.443	-0.467 (-0.914, -0.020)	0.041
	Unclear/unknown	-0.228 (-0.690, 0.234)	0.333	-0.312 (-0.857, 0.234)	0.263
	Worst Pain				
		Pain Interference			
		Estimate (95% CI)	P-Value		
BMI	Underweight	0.319 (-0.163, 0.801)	0.194		
	ref=Normal				
	Weight/Overweight				
	Obese	0.276 (0.104, 0.449)	0.002		
Age		-0.017 (-0.022, -0.013)	0.000		
Pain procedure within 45 days prior		-0.054 (-0.248, 0.141)	0.588		
Opioid prescription within 45 days prior		0.425 (0.263, 0.586)	0.000		
Diagnosis	ref=Muskuloskeletal				
	Neuropathic	-0.151 (-0.392, 0.091)	0.222		
	Other	-0.342 (-0.080, 0.681)	0.030		
	Unclear/unknown	0.300 (0.657, 0.721)	0.122		
	Worst Pain	0.689 (0.657, 0.721)	0.000		

180 **DISCUSSION**

181 **Pain Prevalence**

182 Our study showed that pain clinic patients with obesity experience higher pain severity and pain
183 interference scores than normal weight and overweight patients. Our findings corroborate prior
184 literature that shows that obesity is a risk factor for chronic pain²⁶⁻²⁹, and demonstrates that
185 obesity is an independent risk factor for experiencing more pain severity and pain that may
186 interfere with patients' daily function. Heim et al. reported that in a population of older adults,
187 obese patients were more likely to develop pain, and that the frequency of pain increased more
188 drastically with increased BMI, especially for women³⁰. Their study found that, regardless of
189 weight changes, someone with a higher BMI is more likely to longitudinally develop chronic
190 pain³⁰.

191

192 **Pain Severity**

193 Our study found that obesity was related to pain severity. Patients' rating of worst pain in the last
194 24 hours was statistically significant, with increased pain severity found in obese patients
195 compared to the normal and over- weight patients. Obesity as a risk factor for pain severity has
196 been found in many other studies, ranging from adolescents to geriatric populations^{31;32}. Chronic
197 pain development in an obese population, particularly morbidly obese (BMI>35), after a motor
198 vehicle accident had a significant effect on increasing pain severity during multiple follow-up
199 visits within a year²².

200

201 However, some studies have disputed the relationship between pain severity and obesity^{19;33}.

202 Taspinar et al. did not find obesity to influence pain severity for university students with

203 nonspecific back pain. However, this study included only university students, which limits its
204 generalizability to the wider chronic pain population, which includes patients of a larger age
205 range.

206
207 Looking at the underweight population, the literature agrees with our finding of increased current
208 pain severity in the underweight population compared to the normal group³⁴. Previously, this has
209 also influenced the prescription of opioid medications for pain relief, specifically in cancer
210 populations, but the true clinical relevance has yet to be determined.

211

212 **Pain Interference**

213 Pain severity is related to pain interference, as it is not unexpected that higher levels of pain
214 intensity would have more drastic effects on functioning⁵. In our study, pain interference scores
215 increased with increased ratings of worst pain in the last 24 hours. Pain severity and frequency
216 has been shown to directly predict pain interference and quality of life³⁵⁻³⁷. Of note, our findings
217 contradict with several studies that did not find an association between pain severity and pain
218 interference¹⁹. This finding could be due to a threshold effect that occurs where low levels of pain
219 intensity are not associated with functional interference and where higher levels of pain intensity
220 increase the probability of higher levels of pain interference in a nonlinear fashion⁵⁻⁷.

221

222 In our study, obese patients had higher pain interference than normal weight patients. This
223 follows previous trends finding that obese patients have a higher frequency of pain interference
224 and more severe disability from pain^{19; 29; 32; 36}. Only one study found obesity to be independent of
225 pain interference scores¹⁸.

226
227 While these findings are statistically significant, clinical implication has yet to be determined
228 within this research. Previous literature has speculated that at least a 30% change from baseline
229 on the BPI is required for an impacted quality of life³⁸⁻⁴⁰.

230

231 **Opioid Use**

232 Pain experience is also altered by opioid use, which is commonly prescribed for pain
233 management. Opioid usage was statistically significant between the three BMI categories for
234 both IR and ER medication prescription 45 days prior to the visit. IR medication prescription was
235 more commonly used within all three BMI groups compared to ER medication, with underweight and
236 overweight patients having increased prescriptions compared to the normal weight group. In
237 multivariable modelling, opioid usage was significantly associated with higher pain severity and
238 pain interference. The increase in pain severity and interference increasing with opioid use is
239 unique to our study. A previous study found that opioid medications had no statistically
240 significant difference between BMI (obese or not obese), but opioid use did relate to an increase
241 in pain interference¹⁸. Provider prescriptions of non-steroidal anti-inflammatory drugs used to
242 treat pain found that they are higher amongst obese patients^{16; 17}. Similar to our studies, previous
243 research analyzing the use of opioids and obesity within the context of pain are often limited in a
244 cross-sectional setting due to the unknown timeline of pain characteristics and opioid
245 prescriptions, thus only being able to examine correlation and not causation.

246

247 **Limitations**

248 Our study is limited by retrospective data, multi-institutional data collected primarily from

249 tertiary care centers, and the high prevalence of musculoskeletal pain in our population. Seventy-
250 seven percent of all participants in this study had a diagnosis of musculoskeletal pain, and 79%
251 of obese participants diagnosed with that as well, being only slightly higher than the normal and
252 overweight category (76.0%) and significantly higher than the underweight group (64.7%).
253 Previous literature often restricted cohort populations to those with specific types of pain, like
254 musculoskeletal, since its development has been more easily associated with obesity^{31; 32; 41}.
255 Musculoskeletal pain has also been connected with more pain locations, which is further
256 increased within an obese population^{32; 41}. While a diagnosis of musculoskeletal pain may
257 influence obesity and pain severity scores, it is an extremely prevalent pain diagnosis with
258 clinical implications in both our population and the general population, and thus could not be
259 ignored.

260
261 Our study was also limited by the categorization of weight. For our study, obesity was defined as
262 anyone with a BMI greater than or equal to 30. Further stratification of this obese category has
263 shown trends that indicate greater pain in the severely obese. For McCarthy et al., the severely
264 obese, or those with a BMI of at least 35, were associated with four times the probability of
265 having chronic pain compared to normal patients, whereas those with BMI=30-34.99 were only
266 twice as likely³². This stratification more drastically shows the impact that obesity poses on the
267 experience of chronic pain. Deyo et al. also showed that for those in the top 20%, the prevalence
268 of pain has been found to be significantly higher than those in the bottom 20% of the obese
269 category²⁸.

270

271 Our study only included patients that visited the outpatient pain clinics included in The Registry
272 at least once with BMI information and a diagnosis for the encounter. The survey data analyzed
273 was that of the first survey in the registry for each patient. While the first available BMI value
274 was used as well, this did not consistently align with the first full survey dataset since patients
275 often had multiple pain clinic encounters. By identifying patients retrospectively, we weren't
276 able to follow their progress over more visits longitudinally. In addition, while The Registry is a
277 multi-site database, it gathers information solely from New York City-based sites, which could
278 limit generalizability of our results.

279
280 In addition, our study was not able to capture the prevalence of psychiatric comorbidities within
281 our chronic pain population. Many other studies have found that this dramatically impacts both
282 obesity and pain, often increasing the likelihood or severity of both ^{9-11; 26; 27; 32; 42; 43}. Further
283 research is warranted to assess the role of psychiatric comorbidities on pain interference and
284 severity within a chronic pain population, especially as it may influence management choices
285 and clinical prognosis.

286

287 **Conclusions**

288 Our study demonstrated that pain severity and interference is impacted by obesity and opioid
289 use. The management of chronic pain is multifaceted and complex, particularly in the obese
290 chronic pain population. Our study suggests that these patients' chronic pain is characterized not
291 only by higher pain severity, but also greater interference with activities of daily living. Our
292 findings suggest that counseling patients about their BMI, health maintenance, and setting
293 reasonable expectations in regards to physical functioning and prognosis may improve their pain

294 management treatment in terms of lessening their pain severity and pain interference. Further
295 prospective research is warranted to understand the relationship between reducing BMI and pain
296 interference scores.

297

298

299

300 **ACKNOWLEDGEMENTS**

301 We would like to thank the Weill Cornell Medicine Department of Anesthesiology for their

302 support.

REFERENCES

1. Gaskin DJ, Richard P. The economic costs of pain in the united states. *J Pain* 2012;13:715-24.
2. Relieving pain in america: A blueprint for transforming prevention, care, education, and research. *Mil Med* 2016;181:397-9.
3. Nahin RL. Estimates of pain prevalence and severity in adults: United states, 2012. *J Pain* 2015;16:769-80.
4. Daubresse M, Chang HY, Yu Y et al. Ambulatory diagnosis and treatment of nonmalignant pain in the united states, 2000-2010. *Med Care* 2013;51:870-8.
5. White RS, Jiang J, Hall CB et al. Higher perceived stress scale scores are associated with higher pain intensity and pain interference levels in older adults. *J Am Geriatr Soc* 2014;62:2350-2356.
6. Jensen MP, Smith DG, Ehde DM, Robinsin LR. Pain site and the effects of amputation pain: Further clarification of the meaning of mild, moderate, and severe pain. *Pain* 2001;91:317-22.
7. Woo A, Lechner B, Fu T et al. Cut points for mild, moderate, and severe pain among cancer and non-cancer patients: A literature review. *Ann Palliat Med* 2015;4:176-83.
8. Okifuji A, Hare BD. The association between chronic pain and obesity. *J Pain Res* 2015;8:399-408.
9. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United states, 2015-2016. *NCHS Data Brief* 2017:1-8.
10. Arnstein P, Caudill M, Mandle CL, Norris A, Beasley R. Self efficacy as a mediator of the relationship between pain intensity, disability and depression in chronic pain patients. *Pain* 1999;80:483-91.
11. Zdziarski LA, Wasser JG, Vincent HK. Chronic pain management in the obese patient: A focused review of key challenges and potential exercise solutions. *J Pain Res* 2015;8:63-77.
12. Hitt HC, McMillen RC, Thornton-Neaves T, Koch K, Cosby AG. Comorbidity of obesity and pain in a general population: Results from the southern pain prevalence study. *J Pain* 2007;8:430-6.
13. Briggs MS, Givens DL, Schmitt LC, Taylor CA. Relations of c-reactive protein and obesity to the prevalence and the odds of reporting low back pain. *Arch Phys Med Rehabil* 2013;94:745-52.
14. Schaible HG, von Banchet GS, Boettger MK et al. The role of proinflammatory cytokines in the generation and maintenance of joint pain. *Ann N Y Acad Sci* 2010;1193:60-9.
15. Sommer C, Kress M. Recent findings on how proinflammatory cytokines cause pain: Peripheral mechanisms in inflammatory and neuropathic hyperalgesia. *Neurosci Lett* 2004;361:184-7.
16. Antonov KI, Isacson DG. Prescription and nonprescription analgesic use in sweden. *Ann Pharmacother* 1998;32:485-94.
17. Counterweight Project T. The impact of obesity on drug prescribing in primary care. *Br J Gen Pract* 2005;55:743-9.
18. Anastas T, Colpitts K, Ziadni M, Darnall BD, Wilson AC. Characterizing chronic pain in late adolescence and early adulthood: Prescription opioids, marijuana use, obesity, and predictors for greater pain interference. *Pain reports* 2018;3:e700.
19. Marcus DA. Obesity and the impact of chronic pain. *The Clinical journal of pain* 2004;20:186-91.
20. Eslami V, Katz MJ, White RS et al. Pain intensity and pain interference in older adults: Role of gender, obesity and high-sensitivity c-reactive protein. *Gerontology* 2017;63:3-12.
21. Pazzianotto-Forti EM, Sgariboldi D, Rasera I, Jr., Reid WD. Impact of pain in overweight to morbidly obese women: Preliminary findings of a cross-sectional study. *Physiotherapy* 2018;104:417-423.
22. Mauck MC, Hu J, Sefton C et al. Obesity increases the risk of chronic pain development after motor vehicle collision. *Pain* 2019;160:670-675.

23. Mehta N, Inturrisi CE, Horn SD, Witkin LR. Using chronic pain outcomes data to improve outcomes. *Anesthesiology Clin* 2016;34:395-408.
24. Cleeland CS, Ryan KM. Pain assessment: Global use of the brief pain inventory. *Ann Acad Med Singapore* 1994;23:129-38.
25. Team RC. R: A language and environment for statistical computing. . *R Foundation for Statistical Computing* 2019;Vienna, Austria.
26. Shi Y, Hooten WM, Roberts RO, Warner DO. Modifiable risk factors for incidence of pain in older adults. *Pain* 2010;151:366-71.
27. Ray L, Lipton RB, Zimmerman ME, Katz MJ, Derby CA. Mechanisms of association between obesity and chronic pain in the elderly. *Pain* 2011;152:53-9.
28. Deyo RA, Bass JE. Lifestyle and low-back pain. The influence of smoking and obesity. *Spine* 1989;14:501-6.
29. Rubin DI. Epidemiology and risk factors for spine pain. *Neurologic clinics* 2007;25:353-71.
30. Heim N, Snijder MB, Deeg DJ, Seidell JC, Visser M. Obesity in older adults is associated with an increased prevalence and incidence of pain. *Obesity (Silver Spring, Md)* 2008;16:2510-7.
31. Deere KC, Clinch J, Holliday K et al. Obesity is a risk factor for musculoskeletal pain in adolescents: Findings from a population-based cohort. *Pain* 2012;153:1932-8.
32. McCarthy LH, Bigal ME, Katz M, Derby C, Lipton RB. Chronic pain and obesity in elderly people: Results from the einstein aging study. *J Am Geriatr Soc* 2009;57:115-9.
33. Taspinar F, Taspinar B, Cavlak U, Celik E. Determining the pain-affecting factors of university students with nonspecific low back pain. *Journal of physical therapy science* 2013;25:1561-4.
34. Moryl N, Bokhari A, Griffio Y et al. Does transdermal fentanyl work in patients with low bmi? Patient-reported outcomes of pain and percent pain relief in cancer patients on transdermal fentanyl. *Cancer medicine* 2019;8:7516-7522.
35. Hunfeld JA, Perquin CW, Duivenvoorden HJ et al. Chronic pain and its impact on quality of life in adolescents and their families. *Journal of pediatric psychology* 2001;26:145-53.
36. Lamb SE, Guralnik JM, Buchner DM et al. Factors that modify the association between knee pain and mobility limitation in older women: The women's health and aging study. *Annals of the rheumatic diseases* 2000;59:331-7.
37. Thomas JG, Pavlovic J, Lipton RB et al. Ecological momentary assessment of the relationship between headache pain intensity and pain interference in women with migraine and obesity. *Cephalalgia : an international journal of headache* 2016;36:1228-1237.
38. Atkinson TM, Rosenfeld BD, Sit L et al. Using confirmatory factor analysis to evaluate construct validity of the brief pain inventory (bpi). *Journal of pain and symptom management* 2011;41:558-65.
39. Hoffman DL, Sadosky A, Dukes EM, Alvir J. How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy? *Pain* 2010;149:194-201.
40. Mease PJ, Spaeth M, Clauw DJ et al. Estimation of minimum clinically important difference for pain in fibromyalgia. *Arthritis care & research* 2011;63:821-6.
41. Adamson J, Ebrahim S, Dieppe P, Hunt K. Prevalence and risk factors for joint pain among men and women in the west of scotland twenty-07 study. *Annals of the rheumatic diseases* 2006;65:520-4.
42. Jordan KP, Thomas E, Peat G, Wilkie R, Croft P. Social risks for disabling pain in older people: A prospective study of individual and area characteristics. *Pain* 2008;137:652-61.
43. Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH. The prevalence of chronic pain in united states adults: Results of an internet-based survey. *J Pain* 2010;11:1230-9.

